Biotech stocks notched up impressive gains in the fourth quarter but have had a reality check in January as investors grow more cautious about how pricing policies may play out in Washington ahead of the November U.S. presidential election.Earlier this month, Nektar announced that it plans to initiate new registrational studies to evaluate its drug bempeg in combination with Bristol-Myers Squibb Company's (BMY) inhibitor Opdivo for the treatment of melanoma and bladder cancer.